Several lines of evidence indicate that inhibition of sEH activity provides anti-inflammatory action and thus limits the development of arteriovenous graft stenosis, inflammatory bowel disease, and hepatic steatosis [19, 22, 29]. This evidence concerns the gene EPHX2 and inflammatory bowel disease.